CINCINNATI, Nov. 23--PRNewswire-AsiaNet/InfoQuest
Kendle International Inc. (Nasdaq: KNDL), a leading, global full-service
clinical research organization, today announced the appointment of Ric DeGaris,
PhD, as Country Manager, Australia, effective Jan. 1, 2005. DeGaris replaces
George Mihaly, PhD, who is retiring. In his new role, DeGaris will be
responsible for Kendle's clinical operations in Australia, including business
development, financial performance, clinical project management, human
resources and facilities management. He currently serves as Director, Business
Development for Kendle's Australian operations, a position he has held since
February 2002. Before that, he worked for Kendle as a contract consultant on a
variety of clinical research, regulatory and health outcomes projects.
(Logo: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO )
"Ric possesses a wealth of clinical research and pharmaceutical industry
experience," said Alan Boyce, Vice President, Europe. "He has proven to be a
strong leader and an accomplished business development professional. We look
forward to his continued contributions and thank George for his years of
service in establishing Kendle as a leading CRO in the Asia/Pacific region."
DeGaris was a Founding Director of SYNERmedica Pty. Ltd., an Australian-
based CRO acquired by Kendle in 2000. Before that, he worked for the
Australian subsidiary of pharmaceutical company Farmitalia Carlo Erba (later
acquired by Pharmacia) in a variety of clinical research, medical affairs and
quality assurance positions. In all, DeGaris possesses more than 20 years of
experience within the Australian biopharmaceutical industry.
DeGaris earned his doctorate in pharmacology and his bachelor of science
(Hons), First Class, from Monash University, Australia. He is a member of the
Association of Regulatory and Clinical Scientists, Australian Society for
Reproductive Biology, Australian Society of Clinical and Experimental
Pharmacologists and Toxicologists and Australian Physiological and
Pharmacological Society.
Mihaly founded SYNERmedica in 1994 and under his leadership it became the
largest local clinical research organization in Australia with offices in both
Melbourne and Sydney. He assumed the role of Country Manager upon Kendle's
acquisition of the company. Today, Kendle's Australian operations include
more than 60 associates in Melbourne and Sydney.
About Kendle International Inc.
Kendle International Inc. (Nasdaq: KNDL) is among the world's leading
global clinical research organizations. We deliver innovative and robust
clinical development solutions -- from first-in-man studies through market
launch and surveillance -- to help the world's biopharmaceutical companies
maximize product life cycles and grow market share. With headquarters in
Cincinnati and more than 1,700 associates worldwide, Kendle has conducted
clinical trials or provided regulatory and validation services in more than 60
countries. Investor kits are available upon request from Kendle International
Inc., 1200 Carew Tower, 441 Vine Street, Cincinnati, OH 45202, or from the
company's Web site at http://www.kendle.com .
SOURCE Kendle International Inc.
CONTACT: Investors, Buzz Brenkert, +1-513-345-1525, or Media, Lori Dorer, +1-513-345-1685, both of Kendle International Inc.
FCMN Contact: [email protected]
Photo: NewsCom: http://www.newscom.com/cgi-bin/prnh/20030429/KNDLLOGO
AP Archive: http://photoarchive.ap.org
PRN Photo Desk, [email protected]
Web site: http://www.kendle.com
--Distributed by AsiaNet (www.asianetnews.net)--